Widespread adoption of warfarin prophylaxis for atrial fibrillation requires substantial improvements in service provision and monitoring to prevent more harm than benefit in routine practice.
non-valvar atrial fibrillation
warfarin
Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.
Building similarity graph...
Analyzing shared references across papers
Loading...
Cathie Sudlow
University College Dublin
Helen Rodgers
University of Alberta Hospital
Rose Anne Kenny
General Cardiology
BMJ
Newcastle University
Building similarity graph...
Analyzing shared references across papers
Loading...
Sudlow et al. (Sat,) conducted a review in non-valvar atrial fibrillation. warfarin was evaluated. Widespread adoption of warfarin prophylaxis for atrial fibrillation requires substantial improvements in service provision and monitoring to prevent more harm than benefit in routine practice.
synapsesocial.com/papers/6a15f85d665e751854d13b08 — DOI: https://doi.org/10.1136/bmj.311.7004.558
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: